CellCarta Acquires Reveal Biosciences

Roche to Acquire PathAI to Expand AI-Powered Digital Pathology

May 7, 2026

AI & Machine Learning

Roche has entered into a definitive merger agreement to acquire PathAI, a US digital pathology and AI technology company. The deal is expected to close in the second half of the year and will integrate PathAI’s AISight image management system into Roche’s Diagnostics division.

Agilent Technologies Acquires Biocare Medical

March 9, 2026

Medical Devices

Agilent Technologies entered into a definitive agreement to acquire Biocare Medical, a global provider of clinical and research pathology solutions, for $950 million in an all-cash transaction. The acquisition expands Agilent’s pathology portfolio—particularly in immunohistochemistry (IHC)—and is expected to be accretive to Agilent’s top-line growth rate, margin profile, and non-instrument revenue mix in Year 1.

Carta Healthcare Acquires Realyze Intelligence from UPMC Enterprises

December 9, 2024

Healthcare Services

Carta Healthcare has acquired Realyze Intelligence, a UPMC Enterprises portfolio company. The deal brings Realyze's clinician-trained AI for rapid EHR-based oncology trial matching and data abstraction into Carta's AI-powered clinical data platform to accelerate clinical trial matching and registry abstraction.

Discovery Life Sciences Acquires ReachBio Research Labs

April 11, 2023

Biotechnology

Discovery Life Sciences has acquired Seattle-based ReachBio Research Labs to expand its cell biology, toxicology and drug screening capabilities. The acquisition strengthens Discovery's preclinical development and multi-omics service offering, enabling customers to access a broader set of predictive cell-based assays for hematologic diseases, immunology, oncology and cell & gene therapy programs.

CellCarta Acquires Biogazelle

December 14, 2021

Biotechnology

CellCarta has acquired Biogazelle, a Ghent-based leader in digital PCR (dPCR), qPCR and RNASeq assay development, to strengthen and expand its genomic capabilities. The acquisition creates a Center of Excellence for complex genomic biomarker assay development within CellCarta and broadens its service offering for pharmaceutical and biotech clients across discovery and clinical stages.

K1 Investment Management Acquires Reveal; Reveal Merges with Brainspace

January 26, 2021

AI & Machine Learning

K1 Investment Management has invested in the combined Reveal and Brainspace organization, acquiring Reveal from Gallant Capital Partners and merging Reveal with Brainspace to create a leading AI-powered eDiscovery platform. The combined company will receive more than $200 million of investment from K1 to accelerate product development, expand sales and marketing, and grow R&D and data science capabilities.